Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label Extension Study to Assess the Long-term Safety and Efficacy of TSND-201 for the Treatment of PTSD

NCT07670702 is registered in ClinicalTrials.gov with Transcend Therapeutics as lead sponsor.

NCT NCT07670702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07670702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label Extension Study to Assess the Long-term Safety and Efficacy of TSND-201 for the Treatment of PTSD
Lead sponsor
Transcend Therapeutics
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
June 22, 2026
Completion date
January 31, 2029
Enrollment
300 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

post traumatic stress disorder